Last reviewed · How we verify
NCT05865106
The Efficacy and Feasibility of Smartphone-Based Speech Therapy for People with Post-Stroke Dysarthria
NA trial testing Smartphone-based speech therapy in Dysarthria As Late Effect of Stroke in 76 participants. Completed in 20 May 2024.
20 May 2024
Quick facts
| Lead sponsor | Ewha Womans University Seoul Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 76 |
| Start date | 1 June 2023 |
| Primary completion | 20 May 2024 |
| Estimated completion | 20 May 2024 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Smartphone-based speech therapy
- Traditional speech therapy
Conditions studied
- Dysarthria As Late Effect of Stroke — all drugs for Dysarthria As Late Effect of Stroke →
Sponsor
Ewha Womans University Seoul Hospital
Who can join
18 and older, any sex, with Dysarthria As Late Effect of Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial aims to determine if a new smartphone-based speech therapy is effective and feasible for patients with post-stroke dysarthria. Participants in the intervention group will use the speech therapy app for 1 hour per day, 5 days per week, over a 4-week period. The control group will receive the same duration and frequency of traditional speech therapy as the intervention group. The study will help us understand if smartphone-based speech therapy is a viable treatment option for post-stroke dysarthria patients.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Efficacy and feasibility of a digital speech therapy for post-stroke dysarthria: protocol for a randomized controlled trial.
Kim Y, Kim M, Kim J, Song TJ. · · 2024 · cited 3× · PMID 38356882 · DOI 10.3389/fneur.2024.1305297 -
Efficacy of Digital Speech Therapy for Poststroke Dysarthria: Randomized Noninferiority Trial.
Kim Y, Kim M, Kim S, Kim J, et al · · 2026 · PMID 42149971 · DOI 10.2196/81938
Verify or expand the search:
- PubMed search for NCT05865106
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Ewha Womans University Seoul Hospital trials
Trials by the same sponsor.
- NCT06864052 — The Incidence of New-brain Lesions on Brain MRI and Safety Between Edoxaban and Apixaban in Patients with Stroke and Non · NA · not yet recruiting
- NCT06424548 — Comparison of the Improvement and Safety of the Ankle Brachial Arterial Pressure Index of Sarpogrelate and Clopidogrel i · NA · not yet recruiting
- NCT05146765 — Efficacy of a Digital Therapeutic for People With Dysarthria After Stroke · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05865106 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ewha Womans University Seoul Hospital
- Last refreshed: 30 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05865106.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing